PDSB
PDS Biotechnology Corporation
NASDAQ · Healthcare · Biotechnology · US
$0.22
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | 59.8K | 57.3K | — |
| Gross Profit | — | — | (59.8K) | (57.3K) | — |
| Operating Expenses | |||||
| R&D Expense | 15.7M | 19.0M | 22.6M | 27.8M | 29.4M |
| SG&A Expense | 3.1B | 12.5M | 13.7M | 15.3M | 12.2M |
| General & Admin Expense | 3.1B | 12.5M | — | 15.0M | 12.2M |
| Selling & Marketing Expense | — | — | — | 264.0K | — |
| Other Expenses | (3.1B) | — | — | 1.0K | — |
| Total Operating Expenses | 27.8M | 31.5M | 36.3M | 43.0M | 41.7M |
| Cost and Expenses | 27.8M | 31.5M | 36.3M | 43.0M | 41.7M |
| Operating Income (EBIT) | (27.8M) | (31.5M) | (36.3M) | (43.0M) | (41.7M) |
| Non-Operating | |||||
| Interest Income | 818.0K | 1.2M | 2.5M | 2.9M | 935.2K |
| Interest Expense | 6.7M | 5.3M | 4.7M | 4.2M | 1.3M |
| Net Interest Income | (5.8M) | (4.1M) | (2.2M) | (1.3M) | (381.0K) |
| Other Non-Op Income/Expense | (5.8M) | (4.1M) | (2.2M) | (1.3M) | (381.3K) |
| Non-Operating Income (excl Interest) | (692.6K) | (1.2M) | (2.5M) | (2.9M) | (935.2K) |
| EBT (Pre-Tax Income) | (33.7M) | (35.7M) | (38.5M) | (44.3M) | (42.1M) |
| Income Tax Expense | — | (1.2M) | (869.2K) | (1.4M) | (1.2M) |
| Bottom Line | |||||
| Net Income | (33.7M) | (34.5M) | (37.6M) | (42.9M) | (40.9M) |
| Earnings from Cont. Ops | (33.7M) | (34.5M) | (37.6M) | (42.9M) | (40.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (33.7M) | (34.5M) | (37.6M) | (42.9M) | (40.9M) |
| Per Share | |||||
| Basic EPS | ($0.64) | ($0.74) | ($1.03) | ($1.39) | ($1.43) |
| Diluted EPS | ($0.64) | ($0.74) | ($1.03) | ($1.39) | ($1.43) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 55.7M | 46.4M | 36.5M | 31.0M | 28.6M |
| Diluted Shares Outstanding | 55.7M | 46.4M | 36.5M | 31.0M | 28.6M |
| Profitability Metrics | |||||
| EBITDA | (27.1M) | (30.3M) | (33.7M) | (40.1M) | (40.7M) |
| D&A | 10.9K | 21.8K | 59.8K | 57.3K | 86.00 |
| EBIT | (27.1M) | (30.3M) | (33.8M) | (40.1M) | (40.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026